𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

✍ Scribed by Sebastian Paus; Anne Grünewald; Christine Klein; Michael Knapp; Alexander Zimprich; Bernd Janetzky; Jens C. Möller; Thomas Klockgether; Ullrich Wüllner

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
64 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (__DRD__2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Dopamine D2 receptor TaqIA and TaqIB pol
Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease
✍ Eng-King Tan; Yanni Tan; Anthea Chai; Christopher Tan; Hui Shen; Sau-Ying Lum; S 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 1 views

## Abstract In a case control study, we examined the association of DRD2 Taq1A and Taq1B polymorphisms and risk of PD, and evaluated the strength of linkage disequilibrium of the polymorphisms. The Taq1A and Taq1B polymorphisms were in strong linkage disequilibrium. There was, however, no significa

Allelic association between the DRD2 Taq
Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease
✍ L. Grevle; C. Güzey; H. Hadidi; R. Brennersted; J. R. Idle; J. Aasly 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 3 views

Genes encoding proteins involved in dopaminergic transmission have been of special interest during the evaluation of candidate genes for Parkinson's disease (PD). The dopamine D2 receptor gene (DRD2) is located on chromosome 11 q22-q23, and several polymorphisms of the gene have been described. The

Differential response of speed, amplitud
Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease
✍ Alberto J. Espay; Joe P. Giuffrida; Robert Chen; Megan Payne; Filomena Mazzella; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

## Abstract Although movement impairment in Parkinson's disease includes slowness (bradykinesia), decreased amplitude (hypokinesia), and dysrhythmia, clinicians are instructed to rate them in a combined 0–4 severity scale using the Unified Parkinson's Disease Rating Scale motor subscale. The object

Replacement of dopaminergic medication w
Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long-term observation
✍ Luigi M. Romito; Maria Fiorella Contarino; Nicola Vanacore; Anna Rita Bentivogli 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

## Abstract Stimulation of the subthalamic nucleus (STN) is an effective treatment for advanced Parkinson's disease (PD), but the medication requirements after implant are poorly known. We performed a long‐term prospective evaluation of 20 patients maintained at stable dopaminergic therapy for 5 ye